-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, August 23.
Recently, Hainan Puli Pharmaceutical submitted an application for the imitation of iopamidol injection for the 3 types of imitation listing, and officially entered the contrast agent market
.
According to data from Menet.
com, the terminal contrast agent market for public medical institutions in China will exceed 15 billion yuan in 2020, and currently only two of the top 5 companies are domestic pharmaceutical companies
.
Figure 1: Source of product information declared by Hainan Puli Pharmaceutical: CDE official website iopamidol was developed by Bracco, Italy.
It is a monomeric non-ionic contrast agent with low toxicity to blood vessels and nerves.
And systemic tolerance is good, the osmotic pressure is low, and the injection is also very stable
.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
1 billion yuan.
The epidemic in 2020 will affect the frequency of patient visits, and sales will decline slightly, but still Occupy the TOP5 position of the variety ranking
.
Figure 2: The competitive landscape of iopamidol injection companies in 2020.
Source: Mynet.
com.
The terminal competition landscape of public medical institutions in China.
Before 2015, this product was only imported from the domestic market, and then domestic generic drugs began to be approved.
Beijing Beilu Pharmaceutical, Guangzhou Kangchen Pharmaceutical, Shanghai Stellite Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, Hunan Hansen Pharmaceuticals, and Shandong Kelun Pharmaceuticals have obtained domestic approvals.
The original research drug company Bracco's market share is only about 85%.
.
Table 1: The status of the products that Puli and its subsidiaries have declared for listing and are under review.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database.
Puli Pharmaceuticals is difficult to choose imitation technology in the research and development of new products, and has a good competitive landscape in the future.
Focus on research and development of drugs to ensure that the company continues to launch high-value products
.
According to data from Minai.
com, one of the products declared and under review by the company and its subsidiaries is a class 2.
2 new drug.
Levetiracetam granules are expected to be the first domestic approval.
Generic drugs are reported for production according to the new classification.
Terlipressin injection and sodium nitroprusside injection are expected to hit the country's first imitation
.
Source: CDE's official website and Minet.
com database
review data statistics are as of August 20.
If there are any errors or omissions, please correct me
.
Recently, Hainan Puli Pharmaceutical submitted an application for the imitation of iopamidol injection for the 3 types of imitation listing, and officially entered the contrast agent market
.
According to data from Menet.
com, the terminal contrast agent market for public medical institutions in China will exceed 15 billion yuan in 2020, and currently only two of the top 5 companies are domestic pharmaceutical companies
.
Figure 1: Source of product information declared by Hainan Puli Pharmaceutical: CDE official website iopamidol was developed by Bracco, Italy.
It is a monomeric non-ionic contrast agent with low toxicity to blood vessels and nerves.
And systemic tolerance is good, the osmotic pressure is low, and the injection is also very stable
.
In 2019, the terminal sales of China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
1 billion yuan.
The epidemic in 2020 will affect the frequency of patient visits, and sales will decline slightly, but still Occupy the TOP5 position of the variety ranking
.
Figure 2: The competitive landscape of iopamidol injection companies in 2020.
Source: Mynet.
com.
The terminal competition landscape of public medical institutions in China.
Before 2015, this product was only imported from the domestic market, and then domestic generic drugs began to be approved.
Beijing Beilu Pharmaceutical, Guangzhou Kangchen Pharmaceutical, Shanghai Stellite Pharmaceuticals, Nanjing Zhengda Tianqing Pharmaceuticals, Hunan Hansen Pharmaceuticals, and Shandong Kelun Pharmaceuticals have obtained domestic approvals.
The original research drug company Bracco's market share is only about 85%.
.
Table 1: The status of the products that Puli and its subsidiaries have declared for listing and are under review.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database.
Puli Pharmaceuticals is difficult to choose imitation technology in the research and development of new products, and has a good competitive landscape in the future.
Focus on research and development of drugs to ensure that the company continues to launch high-value products
.
According to data from Minai.
com, one of the products declared and under review by the company and its subsidiaries is a class 2.
2 new drug.
Levetiracetam granules are expected to be the first domestic approval.
Generic drugs are reported for production according to the new classification.
Terlipressin injection and sodium nitroprusside injection are expected to hit the country's first imitation
.
Source: CDE's official website and Minet.
com database
review data statistics are as of August 20.
If there are any errors or omissions, please correct me
.
